What is the expected effect of the $3.8 million aged‑receivables write‑off on the company's net income and cash flow?
Effect of the $3.8 million aged‑receivables write‑off
Accounting area | What happens | Why it matters |
---|---|---|
Net income (the “bottom‑line” on the income statement) | Decreases by roughly $3.8 million (before any tax effect). The write‑off is recorded as an expense (or a reduction of “Other income/expense”) that directly reduces earnings for the quarter. | A lower net‑income figure means the company reports a smaller profit (or a larger loss) for Q2 2025. Investors and analysts will view this as a hit to profitability, even though the amount is non‑cash. |
Cash flow (statement of cash flows) | No cash is actually spent; the $3.8 million is a non‑cash charge. Consequently, in the “Cash flows from operating activities” section the amount is added back to operating cash flow (i.e., cash flow is higher by $3.8 million compared with the cash‑generated amount before the add‑back). | The cash‑flow line shows that the company’s ability to generate cash from its core operations is not impaired by the write‑off. In practice, the cash‑flow impact is neutral – the write‑off reduces reported earnings but improves the operating‑cash‑flow figure because the expense is reversed in the cash‑flow reconciliation. |
Overall cash position | Unchanged by the write‑off itself. Since the receivable was already “aged” (i.e., unlikely to be collected) and is removed from the balance‑sheet, the company does not experience an out‑of‑pocket cash outflow at the time of the write‑off. | The balance‑sheet asset (aged receivable) is reduced, but the cash account is not affected. The only cash‑related effect would be any tax benefit (if the loss is tax‑deductible) that could generate a future cash tax refund, but that is not disclosed in the brief. |
How the mechanics work
Income‑statement impact
- Debit an expense (or credit “Other income”) for $3.8 M.
- Credit the “Allowance for doubtful accounts” (or directly reduce the receivable) for $3.8 M.
- Result: Reduced net income by $3.8 M (pre‑tax). If a corporate tax rate were applied, the after‑tax effect would be slightly less (e.g., at a 25 % tax rate, net‑income would fall by $2.85 M after tax).
- Debit an expense (or credit “Other income”) for $3.8 M.
Cash‑flow statement impact
- In the “Net income” line of the cash‑flow statement, the $3.8 M expense is shown.
- Under “Adjustments to reconcile net income to cash provided by operating activities,” the $3.8 M is added back (or the allowance increase is subtracted) because it did not involve cash.
- Operating cash flow therefore rises by $3.8 M (or by the after‑tax amount if the company adjusts for tax effects).
- In the “Net income” line of the cash‑flow statement, the $3.8 M expense is shown.
Balance‑sheet impact
- Assets: Aged receivable (an asset) is removed, lowering total assets by $3.8 M.
- Equity: Retained earnings (part of equity) fall by the same amount, keeping the accounting equation balanced.
- Assets: Aged receivable (an asset) is removed, lowering total assets by $3.8 M.
Bottom‑line answer to the question
- Net income: The $3.8 million write‑off will reduce the company’s net income for Q2 2025 by roughly $3.8 million (pre‑tax). The reduction may be a bit smaller after accounting for any tax shield.
- Cash flow: Because the write‑off is a non‑cash expense, the company will add the $3.8 million back in the operating‑cash‑flow section, resulting in no cash‑outflow and an increase in reported operating cash flow of the same amount (again, after‑tax adjustments could slightly modify the figure).
Thus, the write‑off hurts reported profitability but does not drain cash; instead, it improves the cash‑flow picture by being a non‑cash charge that is reversed in the cash‑flow reconciliation.
Other Questions About This News
What is the status of the company's pipeline and any upcoming product launches that could drive future sales?
What were the gross margin and operating margin for the quarter, and are there any trends indicating margin compression or expansion?
Is the write‑off a one‑off event or indicative of a broader issue with credit collection that could affect future receivables?
How does CareDx's Q2 revenue growth rate compare to its main competitors in the transplant‑diagnostics space?
What is the cash balance and burn rate post‑quarter, and does the company have adequate liquidity to fund its growth initiatives?
How will the $86.7 million Q2 revenue compare to analyst expectations and consensus estimates?
Did management provide guidance for Q3 or FY 2025, and how does that guidance influence the stock valuation?
How has the market reacted to the release so far, and what volume and price trends are emerging in real‑time trading?
Are there any changes to the capital‑return policy (share repurchases or dividends) that could impact investor sentiment?